Serum proteomic profiling of rheumatoid arthritis–interstitial lung disease with a comparison to idiopathic pulmonary fibrosis. Issue 10 (30th July 2022)

• Record Type: Journal Article
• Authors: Wu, Xiaoping; Jeong, Yunju; Poli de Frías, Sergio; Easthausen, Imaani; Hoffman, Katherine; Oromendia, Clara; Taheri, Shahrad; Esposito, Anthony J; Quesada Arias, Luisa; Ayaub, Ehab A; Maurer, Rie; Gill, Ritu R; Hatabu, Hiroto; Nishino, Mizuki; Frits, Michelle L; Iannaccone, Christine K; Weinblatt, Michael E; Shadick, Nancy A; Dellaripa, Paul F; Choi, Augustine M K; Kim, Edy Y; Rosas, Ivan O; Martinez, Fernando J; Doyle, Tracy J
• Is Part Of: Thorax. Volume 77:Issue 10(2022)
• Page Start: 1041
• Page End: 1044
• Publication Date: 2022-07-30
• Subjects: Interstitial Fibrosis -- Rheumatoid lung disease; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thorax-2021-217822
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Although interstitial lung disease (ILD) causes significant morbidity and mortality in rheumatoid arthritis (RA), it is difficult to predict the development or progression of ILD, emphasising the need for improved discovery through minimally invasive diagnostic tests. Aptamer-based proteomic profiling was used to assess 1321 proteins from 159 patients with rheumatoid arthritis with interstitial lung disease (RA-ILD), RA without ILD, idiopathic pulmonary fibrosis and healthy controls. Differential expression and gene set enrichment analyses revealed molecular signatures that are strongly associated with the presence and severity of RA-ILD and provided insight into unexplored pathways of disease. These warrant further study as non-invasive diagnostic tools and future therapeutic targets.